ストックスクリーナーアプリを入手
83.22
2.41%
1.96
アフターアワーズ：
83.00
-0.22
-0.26%
Nektar Therapeutics (NKTR) 最新ニュース
ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive - Seeking Alpha
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
Nektar Therapeutics stock hits 52-week high at 78.95 USD By Investing.com - Investing.com Canada
Nektar Therapeutics stock hits 52-week high at 78.95 USD - Investing.com
Nektar Therapeutics stock (US6354171056): Is its immunology pipeline strong enough to unlock new ups - AD HOC NEWS
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Certain Restricted Stock Unit of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Stock Options of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Common Stock of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Nektar Therapeutics (HAM:ITH0) Stock Price & 30 Year Financial Data - GuruFocus
NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With ... - Bluefield Daily Telegraph
NKTR Shareholder Alert: Nektar Therapeutics Securities - GlobeNewswire
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
Nektar Therapeutics stock: What investors need to know in immunotherapy's next wave - AD HOC NEWS
Press releases provided by CNW - Techaeris
A Look At Nektar Therapeutics (NKTR) Valuation After Rezpegaldesleukin Trial Progress And Litigation Concerns - Sahm
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Secu - GuruFocus
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Oppo - GuruFocus
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Lawsuit filed for Investors who lost money with shares of Nektar Therapeutics (NASDAQ: NKTR) - openPR.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Nektar Therapeutics to Contact the Firm Today! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein - GlobeNewswire
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
Nektar (NKTR) Poised for Potential Upside with Upcoming Data Rel - GuruFocus
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $123 - 富途牛牛
Nektar Goes Silent: What's Behind The Quiet Period? - RTTNews
Citi Adds Nektar Therapeutics (NKTR) to 30-Day Upside Catalyst Watch List - StreetInsider
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Holzer & Holzer Reminds Investors of Lead Plaintiff Deadlines in Shareholder Lawsuits - National Today
Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff - GlobeNewswire
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Cuts Target Price to $135 - 富途牛牛
Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance UK
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Nektar Therapeutics (NKTR) Is Up 12.1% After REZPEG Data And Lawsuits CollideHas The Bull Case Changed? - Yahoo Finance
Do Rezpegaldesleukin Lawsuits Reframe Nektar Therapeutics' (NKTR) Core Risk Narrative Around Trial Integrity? - simplywall.st
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):